secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2026-08-12T10:59:47+00:00
Accession:  0001104659-26-094433
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q2 2026: YTD revenue $53.6M, net income $22.1M; Elfabrio patent extended to 2035
--------------------------------------------------------------------------------

- Q2 goods revenue $19.8M, up $4.4M YoY on Elfabrio sales; YTD total revenue $53.6M vs $25.8M in 2025
- Year-to-date net income $22.1M, achieving profitability; cash and short-term deposits $40.7M at June 30, 2026
- FY2026 revenue guidance reaffirmed at $78-83M incl. $25M Chiesi milestone; Elfabrio $33-35M, Elelyso $20-23M
- USPTO extended Elfabrio US patent to Nov 17, 2035 (May 4, 2026); South Korea orphan drug designation + MA granted May 2026
- PRX-115 Phase 2 RELEASE enrollment ongoing; top-line results expected H2 2027; USPTO issued uricase patent July 7, 2026

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/0001104659-26-094433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer